Veradermics reported positive results from its Phase 2 study of VDPHL01, an oral treatment for female pattern hair loss, on Wednesday. The study showed that participants experienced significant hair growth within two months of treatment.
Study Details
The Phase 2 Study ‘207’ evaluated VDPHL01 at both a 4.5-milligram once-daily and a twice-daily dose over six months. According to the company, women in the once-daily group saw an average increase of 22.7 hairs per square centimeter, while those in the twice-daily group experienced an increase of 23.3 hairs per square centimeter. By the end of the study, 88.9% of participants in the once-daily arm and 90% in the twice-daily arm reported improvements in hair coverage on the Androgenetic Alopecia Impact Rating Scale.
Safety Profile
Veradermics noted that VDPHL01 maintained a favorable safety profile throughout the study, with no treatment-related serious adverse events reported. The company is currently advancing its late-stage development program, which aims to evaluate the drug in both female and male pattern hair loss. The drug candidate is still in recruitment for a broader pivotal development program.
The positive results from the study could enhance investor sentiment in the biotech sector, particularly for companies focused on dermatological treatments. Increased interest in hair loss therapies may lead to volatility in related stocks as investors react to the potential for FDA approval.
Watch for further updates on the drug's development timeline and any announcements regarding FDA submissions in the coming months.